



# Arcalyst (rilonacept) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE  FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_  
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





# Arcalyst (rilonacept) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
<b>MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):</b>  	<b>DURATION OF THERAPY (SPECIFY DATES):</b>  	<b>RESPONSE/REASON FOR FAILURE/ALLERGY:</b>  
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Familial Cold Auto-inflammatory Syndrome (FCAS) <input type="checkbox"/> Muckle-Wells syndrome (MWS) <input type="checkbox"/> Deficiency of interleukin-1 receptor antagonist(DIRA) <input type="checkbox"/> Other Diagnosis _____ ICD-10 Code(s): _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
<p><b>Will the drug be used in conjunction with a clinical trial?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p><b>Is prescriber a rheumatologist or immunologist?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p><b>Does patient have genetic evidence of an <i>NLRP3</i> mutation?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p><b>Does patient have signs and symptoms of FCAS such as recurrent, intermittent fever and rash that were exacerbated by exposure to generalized cool ambient temperature?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p><b>Does patient have signs and symptoms of MWS such as chronic fever and rash of waxing and waning intensity, sometimes exacerbated by exposure to generalized cool ambient temperature?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p><b>For diagnosis of deficiency of interleukin-1 receptor antagonist(DIRA), answer the following:</b></p> <p><b>Does patient have lab confirmed homozygous mutations of <i>IL1RN</i> causing deficiency of interleukin-1 receptor antagonist?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p><b>Does patient exhibit clinical manifestations of DIRA such as diffuse pustular rash, sterile osteomyelitis, and/or periostitis with articular pain?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p><b>Does patient have any other rheumatic disease or major chronic infectious/inflammatory/immunologic disease such as inflammatory bowel disease, psoriatic arthritis, spondyloarthritis, system lupus erythematosus(SLE)?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p><b>Does patient require maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p><b>Has patient had prior use with non-steroidal anti-inflammatories, methotrexate, and/or corticosteroids?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p> <p><b>Has patient had prior use with at least 3 months of Kineret(anakinra)?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.</p>		





**Arcalyst (riloncept)  
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640**

**MAIL REQUESTS TO:** Magellan Rx Management Prior Authorization Program  
Attn: CP – 4201  
P.O. Box 64811  
St. Paul, MN 55164-0811

